DK1485051T3 - Fremgangsmåde til indgivelse af buprenorphin til behandling af depression - Google Patents

Fremgangsmåde til indgivelse af buprenorphin til behandling af depression

Info

Publication number
DK1485051T3
DK1485051T3 DK03721427T DK03721427T DK1485051T3 DK 1485051 T3 DK1485051 T3 DK 1485051T3 DK 03721427 T DK03721427 T DK 03721427T DK 03721427 T DK03721427 T DK 03721427T DK 1485051 T3 DK1485051 T3 DK 1485051T3
Authority
DK
Denmark
Prior art keywords
depression
buprenorphine
administration
treatment
patients suffering
Prior art date
Application number
DK03721427T
Other languages
Danish (da)
English (en)
Inventor
Robert F Kaiko
Ramiro Sanchez
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1485051T3 publication Critical patent/DK1485051T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK03721427T 2002-03-20 2003-03-20 Fremgangsmåde til indgivelse af buprenorphin til behandling af depression DK1485051T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20
PCT/US2003/008796 WO2003079945A1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Publications (1)

Publication Number Publication Date
DK1485051T3 true DK1485051T3 (da) 2008-09-08

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03721427T DK1485051T3 (da) 2002-03-20 2003-03-20 Fremgangsmåde til indgivelse af buprenorphin til behandling af depression

Country Status (12)

Country Link
US (1) US20030181475A1 (enExample)
EP (1) EP1485051B1 (enExample)
JP (1) JP2005528359A (enExample)
AT (1) ATE394097T1 (enExample)
AU (1) AU2003224742A1 (enExample)
CY (1) CY1108217T1 (enExample)
DE (1) DE60320770D1 (enExample)
DK (1) DK1485051T3 (enExample)
ES (1) ES2305457T3 (enExample)
PT (1) PT1485051E (enExample)
SI (1) SI1485051T1 (enExample)
WO (1) WO2003079945A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
MXPA05006334A (es) * 2002-12-13 2005-08-26 Euro Celtique Sa Dosis de buprenorfina transdermica para analgesia.
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
MY141815A (en) 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
UA81056C2 (en) 2003-07-25 2007-11-26 Euro Celtic S A Method for treatment of dependence withdrawal in pregnant women by transdermal administration of buprenorphine
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
SMT201900357T1 (it) 2009-12-04 2019-07-11 Alkermes Pharma Ireland Ltd Derivati di morfinano per trattamento di abuso di sostanze stupefacenti
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
AU2012351806C1 (en) 2011-12-15 2016-06-16 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP2790703B1 (en) * 2011-12-15 2019-06-12 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
AU2014368548B2 (en) 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DK0484543T3 (da) * 1990-04-24 1996-01-22 Teijin Ltd Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US6165499A (en) * 1996-03-25 2000-12-26 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Also Published As

Publication number Publication date
DE60320770D1 (de) 2008-06-19
EP1485051A1 (en) 2004-12-15
PT1485051E (pt) 2008-07-09
EP1485051B1 (en) 2008-05-07
ATE394097T1 (de) 2008-05-15
AU2003224742A1 (en) 2003-10-08
US20030181475A1 (en) 2003-09-25
SI1485051T1 (sl) 2008-10-31
CY1108217T1 (el) 2014-02-12
JP2005528359A (ja) 2005-09-22
EP1485051A4 (en) 2006-05-24
ES2305457T3 (es) 2008-11-01
WO2003079945A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
EA200401525A1 (ru) Способы лечения гепатита (варианты )
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
DE602004018944D1 (de) Verwendung von abführmittel zur behandlung des reizdarmsyndroms
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
MX2007005065A (es) Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio.
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
DK1638492T3 (da) Præoperativ behandling af postoperativ smerte
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
DE602005024148D1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
EP1795189A3 (en) Method of administering buprenorphine to treat depression
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel
UA3797U (uk) Спосіб лікування тяжких проникаючих поранень ока
CY1113524T1 (el) Μεθοδοι χαμηλης δοσης για τη θεραπεια διαταραχων στις οποιες η δραστικοτητα του tnfα ειναι επιβλαβης
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon